

**Amendments to the Claims:**

The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

Claims 1-13 (Canceled).

Claim 14 (Previously presented): A method of treating a mammal susceptible to a viral, bacterial or parasitic infection by administering a prophylactically safe and effective amount of a immunogenic composition comprising an antigen and/or antigen composition and an adjuvant in the form of an oil in water emulsion, which adjuvant contains a metabolizable oil and alpha tocopherol.

Claim 15 (Previously Presented): The method of claim 14 wherein said antigen or antigenic composition is prepared from the group consisting of Herpes Simplex Virus type 1, Herpes Simplex Virus type 2, Human cytomegalovirus, Hepatitis A, B, C or E, Respiratory Syncytial Virus, Human Papilloma Virus, Influenza Virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium and Toxoplasma, Feline Immunodeficiency Virus, and Human Immunodeficiency Virus.

Claim 16 (Previously Presented): The method of claim 14 wherein said metabolizable oil is squalene.

Claim 17 (Previously presented): The method of claim 14 wherein said immunogenic composition further comprises polyoxyethelene sorbitan monooleate.

Claim 18 (Previously presented): The method of claim 14 wherein said immunogenic composition further comprises a stabilizer.

Claim 19 (Previously Presented): The method of claim 14 wherein the ratio of metabolizable oil:alpha tocopherol is equal to or less than 1.

Claim 20 (Previously presented): A method for treating a mammal having a viral, bacterial or parasitic infection by administering a therapeutically safe and effective amount of an

immunogenic composition comprising an antigen and an adjuvant in the form of an oil in water emulsion which adjuvant contains a metabolizable oil and alpha tocopherol.

Claim 21 (Previously presented): The method of claim 20 wherein said antigen or antigenic composition is prepared from the group consisting of Herpes Simplex Virus type 1, Herpes Simplex Virus type 2, Human cytomegalovirus, Hepatitis A, B, C or E, Respiratory Syncytial Virus, Human Papilloma Virus, Influenza Virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium and Toxoplasma, Feline Immunodeficiency Virus, and Human Immunodeficiency Virus.

Claim 22 (Previously Presented): The method of claim 20 wherein said metabolizable oil is squalene.

Claim 23 (Previously presented): The method of claim 20 wherein the ratio of metabolizable oil:alpha tocopherol is equal to or less than 1.

Claim 24 (Previously presented) The method of Claim 14 wherein the immunogenic composition further comprises QS21 and 3D-MPL.

Claim 25 (Previously presented): The method of Claim 14 wherein the oil in water emulsion comprises from 2 to 10% squalene, from 2 to 10% alpha tocopherol and from 0.3 to 3% polyoxyethylene sorbitan monooleate.

Claim 26 (Currently amended) The method of Claim 25 ~~which~~ wherein the oil-in-water emulsion further comprises QS21 and 3D-MPL.

Claim 27 (Previously presented) The method of Claim 26 wherein the ratio of 3D-MPL to QS-21 is from 2.5:1 to 1:1.